Nventa presents HspE7 data at international HPV conference

    Preclinical Data Indicate New HspE7 Promotes More Potent Immune Responses

    SAN DIEGO, CA, Nov. 5 /CNW/ - Nventa Biopharmaceuticals Corporation
(TSX:NVN) today presented additional preclinical data on new HspE7 at the 24th
International Papillomavirus conference, the largest annual gathering of
scientists, clinicians and companies working in the field of human
papillomavirus (HPV), taking place this week in Beijing, China. HspE7 is being
developed by Nventa as a therapeutic vaccine for the treatment of diseases
caused by HPV. The paper titled, "Th1 CD4 Helper T Cell Immune Responses
Induced by the Combination of HspE7 and the TLR-3 Agonist Poly ICLC", was
presented by Peter Emtage, Ph.D., Vice President of Research and Development
at Nventa.

    Results: Data from the study not only confirmed that the addition of the
TLR3 agonist Poly IC potently alters the magnitude of the antigen-specific CD8
effector arm, but also that adding this moiety acts to push the immune
response into a more potent Th1-biased response. This was demonstrated by a
significant reduction of Interleukin-5 (IL-5) levels seen following
immunization with HspE7 co-administered with Poly IC, compared to those seen
with HspE7 alone. Importantly, the IL-5 decrease was accompanied by a
significant increase in the level of Interferon-gamma (IFN-gamma) in the Poly
IC-containing HspE7 formulations. IFN-gamma is a hallmark cytokine associated
with the generation of Th1-biased immune responses. In addition to the shift
from IL-5 to IFN-gamma, there was also a significant increase in the
generation of antigen-specific IL-2-secreting CD4 helper T cells. In the
study, IgG1, IgG2b and IgG2c antibody responses were dramatically increased as
well by the incorporation of Poly IC to the immunization.
    Dr. Peter Emtage commented on the data: "Taken together, the
antigen-specific increase in CD8 responses, CD4 helper T cell-derived
cytokines, and the antigen-specific increase in IgG2b and IgG2c antibody
isotypes, all clearly demonstrate a potentiated Th1 immune response to the
combination of HspE7 and Poly IC. With our HPV fusion candidate in Phase 1
clinical development using a Poly IC-containing adjuvant, we believe these
data suggest the potential for greater efficacy of HspE7, given that increased
Th1 immune responses typically translate to more balanced and significantly
more potent antiviral and/or anti-tumor activity."

    Background: The development of the appropriate immune response by a host
to an invading pathogen is critical for the control and elimination of the
pathogen. All therapeutic vaccines attempt to recapitulate an anti-pathogen
response by utilizing antigenic fragments from the infectious agent to educate
the immune system. This education results in the targeting of the pathogen by
the effector arms of the host's immune system. Unfortunately, most often in
therapeutic vaccine development, the magnitude of the immune response is less
than desired to effect significant change at the site of infection, be it
chronic or acute. To develop a more robust vaccine strategy, the field has
turned to antigen delivery approaches (e.g. viral and DNA) to "boost" the
initial immune response to levels more appropriate for therapy. An alternative
approach is the use of biological response modifiers or adjuvants. With the
identification of agonists to the Toll-like receptor (TLR) pathways, it has
become possible to not only enhance the magnitude of the immune response, but
also to induce the type of response that favors the mechanism of action that
is needed to clear the infection.
    Nventa has previously shown that HspE7, a proprietary therapeutic vaccine
comprised of a heat shock protein (Mycobaterium bovis BCG Hsp65) linked to the
E7 protein of HPV type 16, when combined with the TLR3 agonist Poly IC, is
capable of inducing potent E7-specific CD8 T cell responses (cellular
responses) and regressing established E7-expressing tumors in mice. In this
new study presented today, the Company investigated whether HspE7 co-injected
with Poly IC is able to induce E7-specific CD4 helper T cell responses
(humoral responses).

    About HspE7, Lead Product Candidate:
    HspE7 is a novel therapeutic vaccine candidate for the treatment of
diseases caused by the human papillomavirus (HPV), one of the most common
sexually transmitted diseases in the world. HspE7 is derived from Nventa's
proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology
to covalently fuse stress proteins to target antigens, thereby stimulating
cellular immune system responses. Heat shock proteins (Hsps), also known as
stress proteins, are naturally present in the human body and play important
roles in the immune system, including transporting substances within cells and
activating cells of the immune system.

    About Nventa Corporation:
    Nventa is developing innovative therapeutics for the treatment of viral
infections and cancer, with a focus on diseases caused by the human
papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock
Exchange under the symbol NVN. For more information about Nventa, please visit

    This press release contains statements which may constitute
forward-looking information under applicable Canadian securities legislation
or forward-looking statements within the meaning of the United States Private
Securities Litigation Reform Act of 1995. Such forward-looking statements or
information may include financial and other projections as well as statements
regarding the Company's future plans, objectives, performance, revenues,
growth, profits, operating expenses or the Company's underlying assumptions.
The words "may", "would", "could", "will", "likely", "expect," "anticipate,"
"intend", "plan", "forecast", "project", "estimate" and "believe" or other
similar words and phrases may identify forward-looking statements or
information. Persons reading this press release are cautioned that such
statements or information are only predictions, and that the Company's actual
future results or performance may be materially different.
    Forward-looking statements or information in this press release include,
but are not limited to, statements or information concerning our belief that
the data produced in the study suggest the potential for greater efficacy of
    Such forward-looking statements or information involve known and unknown
risks, uncertainties and other factors that may cause our actual results,
events or developments to be materially different from results, events or
developments expressed or implied by such forward-looking statements or
information. Such factors include, among others, the possibility that the data
produced in the study do not suggest the potential for greater efficacy of
HspE7, and other factors as described in detail in our filings with the
Canadian securities regulatory authorities at www.sedar.com.
    Assumptions underlying our expectations regarding forward-looking
statements or information contained in this press release include, among
others, that data produced in the study were properly interpreted and that
such data do suggest the potential for greater efficacy of HspE7.
    In the event that any of these assumptions prove to be incorrect, or in
the event that we are impacted by any of the risks identified above, we may
not be able to continue in our business as planned.
    For a complete discussion of the assumptions, risks and uncertainties
related to our business, you are encouraged to review our filings with
Canadian securities regulatory authorities, including our 2006 Annual
Information Form filed on SEDAR at http://www.sedar.com. Historical filings
relating to the Company prior to the completion of the Company's March 23,
2006 corporate reorganization, including Old Stressgen's 2005 Annual
Information Form dated March 16, 2006 may be reviewed on SEDAR at
http://www.sedar.com under the SEDAR profile GVIC Publications Ltd.
    All forward-looking statements and information made herein are based on
our current expectations as of the date hereof and we disclaim any intention
or obligation to revise or update such forward-looking statements and
information to reflect subsequent events or circumstances, except as required
by law.

    %SEDAR: 00023483E

For further information:

For further information: Donna Slade, Director, Investor Relations, 9381
Judicial Drive, Suite 180, San Diego, CA, USA, 92121, Dir: (858) 202-4945,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890